用γ-亚麻酸治疗糖尿病性神经病变。γ-亚麻酸多中心试验组。
Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group.
作者信息
Keen H, Payan J, Allawi J, Walker J, Jamal G A, Weir A I, Henderson L M, Bissessar E A, Watkins P J, Sampson M
机构信息
UMDS, London, UK.
出版信息
Diabetes Care. 1993 Jan;16(1):8-15. doi: 10.2337/diacare.16.1.8.
OBJECTIVE
To compare the effects of placebo and GLA on the course of mild diabetic neuropathy over 1 yr.
RESEARCH DESIGN AND METHODS
We entered 111 patients with mild diabetic neuropathy from seven centers into a randomized, double-blind, placebo-controlled parallel study of GLA at a dose of 480 mg/day. MNCV, SNAP, CMAP, hot and cold thresholds, sensation, tendon reflexes, and muscle strength were assessed by standard tests in upper and lower limbs.
RESULTS
For all 16 parameters, the change over 1 yr in response to GLA was more favorable than the change with placebo, and for 13 parameters, the difference was statistically significant. Sex, age, and type of diabetes did not influence the result, but treatment was more effective in relatively well-controlled than in poorly-controlled diabetic patients.
CONCLUSIONS
GLA had a beneficial effect on the course of diabetic neuropathy.
目的
比较安慰剂和γ-亚麻酸（GLA）对轻度糖尿病性神经病变病程超过1年的影响。
研究设计与方法
我们从7个中心纳入了111例轻度糖尿病性神经病变患者，进行一项随机、双盲、安慰剂对照的平行研究，给予剂量为480毫克/天的GLA。通过标准测试评估上下肢的运动神经传导速度（MNCV）、感觉神经动作电位（SNAP）、复合肌肉动作电位（CMAP）、冷热阈值、感觉、腱反射和肌肉力量。
结果
对于所有16项参数，GLA治疗1年的变化比安慰剂更有利，且13项参数的差异具有统计学意义。性别、年龄和糖尿病类型不影响结果，但在血糖相对控制良好的糖尿病患者中治疗效果比控制不佳的患者更有效。
结论
GLA对糖尿病性神经病变病程有有益影响。
Zotero 插件